## Most Commonly Used Alpha Blocker in BPH **Key Point:** Tamsulosin is the most frequently prescribed alpha blocker for benign prostatic hyperplasia worldwide and in India, owing to its superior selectivity and tolerability profile. ### Why Tamsulosin Dominates Clinical Practice **High-Yield:** Tamsulosin is a **uroselective alpha-1A antagonist** with the following advantages: - Selective for alpha-1A receptors in prostatic smooth muscle (minimal vascular effects) - Lowest incidence of orthostatic hypotension and syncope compared to non-selective agents - Once-daily dosing (0.4 mg) improves compliance - Rapid symptom relief with minimal systemic side effects ### Comparison of Alpha Blockers in BPH | Agent | Selectivity | Dosing | Common AE | Clinical Use | | --- | --- | --- | --- | --- | | **Tamsulosin** | Alpha-1A selective | 0.4 mg OD | Minimal hypotension | **First-line** | | Doxazosin | Non-selective | 1–8 mg OD | Hypotension, dizziness | Second-line | | Terazosin | Non-selective | 1–10 mg OD | Hypotension, syncope | Second-line | | Prazosin | Non-selective | 0.5–2 mg TDS | Marked hypotension, reflex tachycardia | Rarely used in BPH | **Clinical Pearl:** Prazosin is rarely used for BPH because it causes significant orthostatic hypotension and requires three-times-daily dosing, making it impractical. It is reserved for hypertension management (though also second-line there). **Mnemonic:** **TAUT** — **T**amsulosin is **A**lpha-1A **U**roselective for **T**herapy (first-line for BPH). ### Mechanism of Benefit Alpha-1A receptors in the prostate and bladder neck mediate smooth muscle contraction. Selective blockade relieves dynamic obstruction without causing systemic vasodilation, thereby avoiding the orthostatic hypotension seen with non-selective agents like doxazosin and terazosin.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.